Ann: Sale of 1.5 million units through CanView, page-19

Might just be informed investors accumulating to increase their position in an undervalued company.

Luxury rules: Farr-Jones shrugs off recession talk
https://archive.is/fBEOl

To add to her esoteric portfolio, Farr-Jones began investing this year in medical cannabis wholesale distributor Vitura Health. The company has a market cap of about $226 million after falling 20 per cent so far this year.

She took a position after a few founder sell-downs meant the fund could buy Vitura on the cheap. Like Cettire, it’s also not capital-intensive because it doesn’t manufacture anything.
"We have typically struggled with medicinal cannabis because ... there’s huge capex that’s involved in the manufacturing, getting licensing for the manufacturing, developing a product etc. It’s capital intensive. We don’t like that part of the value chain.
[Virtura] are a first mover so at the moment they get to enjoy very high margins. I think it’s very under-owned in the Australian market. Not many brokers cover it, it’s one that’s flying under the radar a little bit."


How your next prescription could be mushrooms or ecstasy
https://open.spotify.com/episode/5z0cjc2K4llGE61wVwhvpY?si=ynyAI0_KT9Kn0Z618J1DRw

The psychedelic drugs psilocybin and MDMA, commonly known as magic mushrooms and ecstasy, are being downgraded from prohibited to controlled drugs in Australia from July 1. This means approved psychiatrists will be able to prescribe psilocybin for depression and MDMA for PTSD.

It's a landmark moment in the regulation of psychedelic drugs for treating entrenched mental illness, Rodney Cocks, CEO of Vitura Health joins Jan Fran to explain why.